Bedminster, N.J., Sept. 04, 2026 Globe Newswire -- Matinas BioPharma Holdings, Inc. the Company NYSE American MTNB announced today that on August 31, 2026, it received a notice the Notice from the NYSE American LLC the N
Why Is Matinas BioPharma Holdings, Inc. (MTNB) Stock Down Today?
Updated Nov 19, 2026 6:15 PM ET · Prev Close $0.91
Session Regime & Catalyst Assessment
68% Signal ConvictionMatinas BioPharma Holdings, Inc. Pulling Back 10.98% on 0.38x Relative Volume
Matinas BioPharma Holdings, Inc. (MTNB) is pulling back 10.98% (-$0.10) to $0.81 on 0.38x average session volume. Relative to benchmarks, MTNB is lagging the S&P 500 by -9.02%. 14-day RSI stands at 33.0, keeping momentum in a bearish regime.
Bedminster, N.J., Sept. 04, 2026 Globe Newswire -- Matinas BioPharma Holdings, Inc. the Company NYSE American MTNB announced today that on August 31, 2026, it received a notice the Notice from the NYSE American LLC the N
Price ($0.81) trades relative to 20-day SMA ($1.26) and 50-day SMA ($1.47).
Market & Sector Relative Strength
MTNB lagging the S&P 500 by -9.02%Options Flow & Execution Desk
Recent MTNB Catalyst Headlines
Verified WireToronto, July 13, 2026--GH Power Inc. and Matinas BioPharma Holdings, Inc enter into Business Combination Agreement.
Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization Business Combination expected to provide public market pl
Bedminster, N.J., June 26, 2026 Globe Newswire -- Matinas BioPharma Holdings, Inc. the Company NYSE American MTNB announced today that on June 24, 2026, it received a notice the Notice from the NYSE American LLC the NYSE
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.81 (session support) for directional breakout confirmation.
Technical Regime (MTNB)
BEARISH MA TRENDRetail & Crowd Sentiment
QuietICMB, the Twitter handle of a bullish trader, expressed optimism towards $MTNB stock, highlighting its low float, clean balance sheet, positive cash flow, and significant assets. No recent news articles were available.
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Get Instant MTNB Catalyst Alerts
Receive an email alert when MTNB triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversMTNB Session & Catalyst FAQ
Why is MTNB stock down today?
Matinas BioPharma Holdings, Inc. (MTNB) is pulling back 10.98% (-$0.10) to $0.81 on 0.38x average session volume. Relative to benchmarks, MTNB is lagging the S&P 500 by -9.02%. 14-day RSI stands at 33.0, keeping momentum in a bearish regime.
Is MTNB stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.38x relative volume (low participation). Our multi-factor model currently rates MTNB as HOLD. Review full valuation, quality, and timing signals on the MTNB Buy or Sell Decision Brief →
What is MTNB's intrinsic value and expected trading range?
At $0.81, MTNB's modeled 1-to-3 session range is $0.77 – $0.85, with a key inflection level at $0.81 (session support). Compare current price against multi-year cash flow projections in the MTNB Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for MTNB?
RSI at 33.0 reflects soft below-midline momentum. MTNB trades at $0.81 relative to its 20-day SMA ($1.26) and 50-day SMA ($1.47), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.